{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T22:03:32Z","timestamp":1770156212466,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":85,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG066722"],"award-info":[{"award-number":["AG066722"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22ama121038"],"award-info":[{"award-number":["JP22ama121038"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22zf0127007"],"award-info":[{"award-number":["JP22zf0127007"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JPMJFR215T"],"award-info":[{"award-number":["JPMJFR215T"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JPMJMS2023"],"award-info":[{"award-number":["JPMJMS2023"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>\n                      Neuropsychiatric syndromes such as anxiety and agitation are clinical presentations common to diverse neurodegenerative diseases and brain injury sequelae. They are a concern due to the impact on cognition, social interactions, and non\u2010pharmacological treatments. Cognitive or behavioral disturbances occur at early disease stages and increase with disease progression. Coincident pathologies include the loss of serotonin (5\u2010HT) neurons and appearance of neurofibrillary tangles in the raphe nucleus. Brain 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      receptor (5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R) levels are increased in Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and post\u2010stroke morbidity.\n                      <jats:italic>HTR2B<\/jats:italic>\n                      gene variants are implicated in psychiatric disorders. 5\u2010HTRs are associated with atypical neurotropic drug mechanisms and behavioral dysfunction in drug abuse. The accumulating body of evidence suggests that selective 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R inhibition might mitigate neuropsychiatric syndromes and the associated cognitive dysfunction. Atypical neurotropic drugs interact with a variety of monoamine receptors and outcomes are viewed as a combination of 5\u2010HT and dopamine D2 receptor mediated actions. Clearly, there is a need for insight into precision 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R inhibition as a potential pharmacological mechanism for treatment of neuropsychiatric syndromes and cognitive dysfunction associated with dementia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Strategic optimization of an atypical neurotropic drug was used to develop MW073, a highly selective and orally bioavailable inhibitor of 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R activity and \u03b2\u2010arrestin\u20101 recruitment that is devoid of dopamine receptor recognition and risk of 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R agonist activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      MW073 ameliorates amyloid and tau induction of behavioral dysfunction in preventive or disease stage intervention paradigms. Using MW073 as a standard of comparison, risperidone was shown to be a dose\u2010dependent inhibitor 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R activity and \u03b2\u2010arrestin\u20101 recruitment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>\n                      Selective inhibition of 5\u2010HT\n                      <jats:sub>2b<\/jats:sub>\n                      R activity is a viable mechanism for the treatment of neuropsychiatric syndromes with synaptic dysfunction as a root cause and is a previously unrealized pharmacodynamic mechanism potentially embedded in current neurotherapeutics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            A new highly selective 5\u2010HT\n                            <jats:sub>2b<\/jats:sub>\n                            R antagonist, MW073, is described and used as a reference standard.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>MW073 attenuates synaptic and behavioral dysfunctions an animal models of neuropsychatric syndromes.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Risperidone is a dose dependent inhibitor of 5\u2010HT\n                            <jats:sub>2b<\/jats:sub>\n                            R activity and arrestin recruitment.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70073","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T01:01:40Z","timestamp":1743296500000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimized 5\u2010HT\n                    <sub>2b<\/sub>\n                    inhibitors for neuropsychiatric syndromes with cognitive dysfunction"],"prefix":"10.1002","volume":"11","author":[{"given":"Saktimayee M.","family":"Roy","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Acquarone","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer's Disease and the Aging Brain  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elentina K.","family":"Argyrousi","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer's Disease and the Aging Brain  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer's Disease and the Aging Brain  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Staniszewski","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer's Disease and the Aging Brain  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Inoue","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences Tohoku University  Sendai Japan"},{"name":"Graduate School of Pharmaceutical Sciences Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Ziarek","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"Arancio","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer's Disease and the Aging Brain  New York New York USA"},{"name":"Departments of Medicine and Pathology and Cell Biology Columbia University  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7605-5866","authenticated-orcid":false,"given":"D. Martin","family":"Watterson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010021\u201000591\u20109"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2024.01.024"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010240125"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2410"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001238"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13449"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102990.2009.00997.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2017.05.007"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0305\u20101846.2000.00291.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e318232a379"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8277"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws274"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010240063"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09629"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0198\u2010097"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20101"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137040"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5291\u201004.2005"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066226"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20101\u20104939\u20107816\u20108_7"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398\u2010024\u201002847\u20106"},{"key":"e_1_2_9_23_1","unstructured":"FDA. RISPERDAL\u00ae (risperidone) prescribing information.U.S. Food and Drug Administration;2010. Accessed August 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020588s046lbl.pdf"},{"key":"e_1_2_9_24_1","unstructured":"FDA.Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trialsfor Therapeutics in Adult Healthy Volunteers.U.S. Food and Drug Administration;2005. Accessed August 2024.https:\/\/www.fda.gov\/media\/72309\/download"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl0998"},{"key":"e_1_2_9_26_1","unstructured":"FDA. 2006 INVEGA\u00ae.INVEGA\u00ae (paliperidone) prescribing information.U.S. Food and Drug Administration;2010. Accessed December 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021999s018lbl.pdf"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:17:19Z","timestamp":1761491839000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/trc2.70073"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70073","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70073"}}